Skip to main content
Careers
Partners
Investors
Contact
Globe
Menu
Menu
Close
Close
Company
Expand mega menu
Expand submenu
Left
Back
Company
WHO WE ARE
Expand
About Lilly
Recognitions
LEADERSHIP
Expand
Governance
Executive Committee
Board of Directors
POLICIES & REPORTS
Expand
Public Policy
Integrated Summary Report
Annual Report & Proxy Statement
Our Tax Principles
Science
Expand mega menu
Expand submenu
Left
Back
Science
DISCOVERY
Expand
Clinical Development Pipeline
Research & Scientific Discovery
Principles of Medical Research
DISEASE AREAS
Expand
Diabetes
Cancer
Immunology
Pain
Neurodegeneration
CLINICAL RESEARCH
Expand
Clinical Trials
Lilly TrialGuide
Expanded Access
CSR Synopses
PARTNERS
Expand
Collaborate With Us
Scientific Partnering Areas of Interest
Office of Alliance Management
Chorus R&D
Lilly Research Award Program
Medicines
Expand mega menu
Expand submenu
Left
Back
Medicines
SAFETY
Expand
Patient Safety
Medication Safety
OUR MEDICINES
Expand
Current Medicines
Historic Medicines
Suggestions for Patients
Manufacturing & Quality
RESOURCES
Expand
Lilly Diabetes Solution Center
Lilly Pricing Information
The Lilly Answers Center
Lilly Cares Foundation
Responsibility
Expand mega menu
Expand submenu
Left
Back
Responsibility
EXTENDING OUR IMPACT
Expand
Lilly Foundation
Lilly Grant Office
OPERATING RESPONSIBLY
Expand
Our Responsibility
Diversity & Inclusion
Ethics & Compliance
Environmental Sustainability
SOCIAL IMPACT
Expand
Our Approach
Global Health
Communities
Disaster Relief
News
Expand mega menu
Expand submenu
Left
Back
News
STORIES
Expand
Caring
Science
Policy
All Stories
PRESS RELEASES
Expand
Recent
Archives
MEDIA
Expand
All News
Media Contacts
Media Kits
Search
Careers
Partners
Investors
Contact
Globe
Media Kits
REYVOW™ (lasmiditan) C-V: A First-in-Class Acute Treatment for Migraine Is Now Available
Learn More
